^
Association details:
| Biomarker: | BRCA2 exon 11 deletion |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Title:
Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance
Published date:
02/19/2021
Excerpt:
We present the case of a 65-yr-old man with a germline BRCA2 mutation who developed explosive treatment-emergent, small-cell neuroendocrine prostate cancer. He achieved a complete response to platinum-containing chemotherapy, but a limited remission duration with the use of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, as maintenance therapy. Upon relapse, tumor genomic profiling revealed a novel 228-bp deletion in exon 11 of the BRCA2 gene.
DOI:
10.1101/mcs.a005801s
